China just approved the world's first commercial brain-computer interface implant, beating Neuralink to full regulatory clearance. The device lets paralyzed patients control a robotic glove with their thoughts, and it's heading to hospitals now.
Imagine being paralyzed from the neck down, unable to hold a cup of coffee. Now imagine a coin-sized chip on your brain that reads your thoughts and lets a robotic glove do the gripping for you. That's not science fiction anymore. It just got approved for sale in China.
On March 13, 2026, China's National Medical Products Administration (NMPA) gave commercial approval to NEO, the world's first invasive brain-computer interface (BCI) cleared for everyday medical use. Not a research exemption. Not an investigational device. A full, sell-it-to-hospitals, use-it-on-patients commercial green light.
Neuralink has been grabbing headlines for years. But while Elon Musk's company is still running clinical trials in the U.S., a Shanghai-based company called Neuracle Technology (also known as Borui Kang Medical Technology) quietly crossed the regulatory finish line first.
A Chip That Reads Your Mind (Sort Of)
Let's talk about what NEO actually does, because it's genuinely wild.
Doctors implant a small wireless sensor on the surface of your brain's motor cortex, the region that controls movement. Crucially, it sits on top of the brain tissue rather than piercing into it, making the procedure minimally invasive. Think of it like placing a microphone on the outside of a wall to hear what's happening inside the room.
That sensor picks up neural signals: the electrical patterns your brain fires when you intend to move your hand. Those signals get beamed wirelessly to a processor, which decodes them in real time and translates them into commands for a pneumatic robotic glove. The result? A paralyzed person thinks "grab that cup," and the glove does it for them.
Patients can operate the system independently at home about one month after surgery. No wires. No lab technicians hovering nearby. Just a person regaining a piece of their life.
Who's Eligible (and Who Isn't)
NEO isn't for everyone. The approval targets a specific population: adults aged 18 to 60 with severe spinal cord injuries causing quadriplegia or partial paralysis. Patients need to have been diagnosed at least one year prior, with their condition stable for six months after standard treatment. They also need to retain some upper arm function, even if they can't grip objects.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
That last requirement matters. NEO doesn't replace all motor function. It's a bridge between "I can move my arm but can't close my hand" and "now I can hold things again." For someone who hasn't grasped an object in years, that bridge is everything.
The Clinical Evidence Behind the Approval
This wasn't a rubber-stamp situation. Neuracle ran 36 procedures across China's hospital system: four feasibility trials followed by 32 multicenter studies conducted under Good Clinical Practice (GCP) standards. Every single patient in those trials showed improvements in grasping ability.
Some patients even showed signs of neural adaptation, meaning their brains appeared to partially rewire in response to using the device. That's a tantalizing hint that BCIs might do more than compensate for lost function; they might help the brain heal itself. (To be clear, that's an early observation, not a proven therapeutic claim.)
The trial data also showed that patients could transition to independent home use relatively quickly. Within about a month of surgery, participants were controlling the robotic glove on their own, performing daily tasks like picking up objects and holding cups.
Why China Got There First
The U.S. has been the undisputed leader in neurotechnology for decades. Neuralink started human trials in 2023 and received FDA Breakthrough Device designation for speech restoration. Blackrock Neurotech has been used in research settings for years. Synchron developed a clever stent-based BCI that doesn't require open brain surgery.
But none of them have full commercial approval. Not one.
China's advantage wasn't necessarily the technology. It was the regulatory infrastructure. Beijing has been treating BCI as a strategic national priority, on par with AI and quantum computing. In July 2025, seven government agencies (including the NMPA) released an implementation plan for "Promoting Innovation and Development of the BCI Industry," with targets for breakthroughs by 2027 and industry standards by 2030.
The NMPA also created a fast-track pathway called the Special Review Procedure for Innovative Medical Devices, essentially a green channel for first-in-class products. In September 2025, the agency published China's first national standard for BCI terminology, creating a unified language for developers, regulators, and clinicians. In 2025, another Chinese BCI company (Shanghai Step Medical Technology) had its implantable system accepted into that fast-track pathway.
The whole apparatus was designed to move quickly. And it did.
The Neuralink Comparison Everyone's Making
It's impossible to talk about NEO without talking about Neuralink, so let's put them side by side.
Neuralink's device is a fully invasive implant. Its electrode threads penetrate directly into the brain's cortex, offering roughly 1,000 recording channels. That higher channel count enables more versatile control: patients in Neuralink's trials have used brain signals to move cursors, type, and communicate. The tradeoff is a more invasive surgical procedure.
NEO takes a different approach. Its electrodes sit on the brain's surface (epidural placement), which is less invasive but captures signals with lower resolution. The device is narrowly focused on one task: restoring hand grasping function through a robotic glove. It's less flashy than cursor control, but for someone who can't hold a fork, it's profoundly practical.
Think of it this way: Neuralink is building a smartphone (versatile, powerful, complex), while Neuracle built a really good landline phone (does one thing, does it well, and it's available now).
Wall Street Noticed
The approval sent shockwaves through Hong Kong's stock market. BCI-exposed companies saw shares surge in the days following the announcement. Investors are clearly betting that this is the start of something much bigger.
Analysts project China's BCI market could reach $800 million by 2027. That number becomes more plausible when you consider the approval pathway Neuracle just blazed. Other Chinese BCI companies now have a regulatory template to follow, and provincial governments in Sichuan, Hubei, and Zhejiang have already established medical service pricing for BCI procedures, laying the groundwork for future insurance inclusion.
The Bigger Picture
This approval matters beyond just one device or one company. It signals a shift in the global neurotechnology landscape.
For years, the implicit assumption has been that the U.S. would set the pace for BCI commercialization. American companies had the best researchers, the most funding, and the loudest megaphones. What they didn't have was a regulatory environment optimized for speed. The FDA's process is thorough (and for good reason), but it's also slow. China saw that gap and drove straight through it.
The competitive pressure this creates could actually benefit patients everywhere. If Chinese BCIs start reaching hospitals while American devices remain stuck in trials, expect the FDA to face mounting pressure to streamline its own approval pathways. A BCI expert told Reuters that practical public use of these devices could emerge within three to five years as products mature, and China's head start makes that timeline feel more concrete.
Over 50 flexible implantable BCI clinical trials had been completed in China by mid-2025, spanning invasive, semi-invasive, and noninvasive approaches. The pipeline behind NEO is deep.
What Comes Next
NEO's approval is narrow by design: one specific patient population, one specific function. But it's a regulatory beachhead. Neuracle and its competitors will push to expand indications, improve signal resolution, and extend BCI applications to stroke rehabilitation, communication for ALS patients, and eventually, broader motor restoration.
Long-term safety data is still limited; these are early days. The 32-patient multicenter trial was enough for approval, but post-market surveillance will be critical. How do these implants perform after two years? Five? That data simply doesn't exist yet.
Still, it's worth stepping back and appreciating what just happened. A paralyzed person in China can now receive a commercially approved brain implant, go home, think about moving their hand, and watch a robotic glove do it for them. That sentence would have sounded absurd five years ago.
The BCI race isn't over. It just got its first official winner.
4 min read
Vertex Bet $5 Billion on a Kidney Drug. It Just Paid Off.
Vertex dropped $4.9 billion on a kidney drug most people had never heard of. Two years later, the Phase 3 data just landed, and it's turning heads across the IgA nephropathy space. The stock hit a record high.
